No Record Found
Sector
PharmaceuticalsOpen
₹169.79Prev. Close
₹169.48Turnover(Lac.)
₹122.14Day's High
₹172.2Day's Low
₹16852 Week's High
₹326.7552 Week's Low
₹154.06Book Value
₹90.08Face Value
₹10Mkt Cap (₹ Cr.)
820.32P/E
31.38EPS
5.41Divi. Yield
1.77No Record Found

| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 48.29 | 48.21 | 48.21 | 48.21 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 383.15 | 368.66 | 347.38 | 330.51 |
Net Worth | 431.44 | 416.87 | 395.59 | 378.72 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 204.52 | 222.83 | 179.29 | 153.69 |
yoy growth (%) | -8.21 | 24.28 | 16.65 | -15.33 |
Raw materials | -127.82 | -137.74 | -101.16 | -91.24 |
As % of sales | 62.5 | 61.81 | 56.42 | 59.36 |
Employee costs | -21.05 | -18.33 | -20.02 | -18.33 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 16.16 | 32.7 | 15.73 | 6.96 |
Depreciation | -4.32 | -4.1 | -3.47 | -3.22 |
Tax paid | -4.42 | -9.23 | -4.51 | -2.25 |
Working capital | 53.98 | -10.52 | 14.2 | -0.58 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -8.21 | 24.28 | 16.65 | -15.33 |
Op profit growth | -48.96 | 30.3 | 158.76 | -48.38 |
EBIT growth | -47.64 | 68.3 | 59.58 | -41.25 |
Net profit growth | -49.96 | 109.2 | 138.37 | -44.65 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 629.6 | 614.59 | 550.99 | 477.52 | 491.81 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 629.6 | 614.59 | 550.99 | 477.52 | 491.81 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 3.98 | 14.61 | 3.07 | 10.6 | 17.99 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,689.9 | 81.36 | 4,05,247.68 | 753.53 | 0.95 | 5,566.68 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,565.5 | 74.56 | 1,74,176.59 | 557 | 0.46 | 2,357 | 561.08 |
Cipla Ltd CIPLA | 1,645.1 | 25.73 | 1,32,897.65 | 1,303.13 | 0.97 | 4,501.66 | 397.38 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,614.1 | 61.58 | 1,22,422.06 | 551 | 0.17 | 2,567 | 224.34 |
Dr Reddys Laboratories Ltd DRREDDY | 1,279.4 | 15.5 | 1,06,818.04 | 2,961.2 | 0.62 | 7,788.7 | 345.74 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Non Executive Dir.
Susheel G Somani
Vice Chairman & Executive Dire
Surendra Somani
Non Executive Director
Adarsh Somani
Non Executive Director
Varun Somani
Independent Non Exe. Director
Siddhan Subramanian
Independent Non Exe. Director
Sunita Banerji
Independent Non Exe. Director
Mamta Biyani
Independent Non Exe. Director
Narayan Atal
Independent Non Exe. Director
Chandresh Gandhi
Company Sec. & Compli. Officer
Sunil Sodhani
Parijat House 1076,
Dr E Moses Road Worli,
Maharashtra - 400018
Tel: 91-22-43661111
Website: http://www.kopran.com
Email: sunil@kopran.com
Office No 56-2,
Pinnacle Busine.Park, Mahakali Caves Road,
Mumbai - 400093
Tel: 91-22-62638200
Website: www.bigshareonline.com
Email: investor@bigshareonline.com
Summary
Kopran Ltd., incorporated on April 26, 1958, was promoted by the Somani group and is controlled by Parijat Enterprises. The company came out with a public issue at a premium, in Nov.92, to finance its...
Read More
Reports by Kopran Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.